Skip to content
Research Article Open access CC BY 4.0

Visceral Leishmaniasis Treatment and Its Challenges

Israt Jahan Khan Chowdhury, Md Fazlul Haque

South Asian Journal of Parasitology · pp. 307–322 · Published 1 Apr 2020

Abstract

Visceral leishmaniasis (VL) is generally termed as kala-azar, black fever, and Dumdum fever and it is known to be the most severe form of leishmaniasis. Without any proper diagnosis and treatment it causes high fatality rate. It is a disease generally caused by protozoan parasites of genus Leishmania. Miltefosine is the first oral treatment for this disease. The cure rate of miltefosine in Phase III clinical trials is 95%. This review is focused on the drugs available for the treatment of VL, their effectiveness and future challenges.

Leishmaniasis leishmania visceral treatment.

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.